|Trade names||Gestovis, Gestovister|
|Synonyms||PGA; Gestovis; 17α-Acetoxyprogesterone 3-cyclopentyl enol ether|
|Drug class||Progestin; Progestogen; Progestogen ether; Progestogen ester|
|Chemical and physical data|
|Molar mass||440.615 g/mol g·mol−1|
|3D model (JSmol)|
Pentagestrone acetate (PGA), sold under the brand names Gestovis and Gestovister, is a progestin which was described in the literature in 1960 and was introduced by Vister in Italy in 1961. It is the 3-cyclopentyl enol ether of 17α-hydroxyprogesterone acetate. PGA, along with quingestrone (the 3-cyclopentyl enol ether of progesterone), is said to have very similar properties to those of dydrogesterone, a pure progestogen and close analogue of progesterone.
PGA is orally active, was provided in 10 and 20 mg capsules, and has been used to treat habitual abortion and menstrual disorders at a dosage of 10 to 20 mg/day. It has been said to have equivalent potency to intramuscular progesterone. The combination of 20 mg/day PGA and 100 μg/day mestranol is an effective ovulation inhibitor in women. The effective dosage of PGA in the menstrual delay test has been studied.
- J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 943–. ISBN 978-1-4757-2085-3.
- Drugs Available Abroad. Gale Research. 1991. ISBN 978-0-8103-7177-4.
- P. H. List; L. Hörhammer (12 March 2013). Chemikalien und Drogen Teil A: N-Q. Springer-Verlag. pp. 508–. ISBN 978-3-642-65035-2.
- Camille Georges Wermuth (2 May 2011). The Practice of Medicinal Chemistry. Academic Press. pp. 731–. ISBN 978-0-08-056877-5.
- Revue générale des sciences pures et appliquées et bulletin de l'Association française pour l'avancement des sciences. Société d'édition d'enseignement supérieur. 1964.
[[...] Ercoli (1960) developed cyclopentyl enol ethers of progesterone (Luteovis) and acetoxy progesterone (Gestovis), which have almost exactly the same properties as dydrogesterone.]
- "Gestovis". South African Medical Journal. 40 (5): 99. January 1966. ISSN 0256-9574.
Comopharm (Pty) Limited. on behalf of Vister Laboratories, announce the introduction of Gestovis, and supply the following information: Gestovis is a new highly effective oral progesterone derivative (cyclopentylenol-ether of 17-alpha-acetoxyprogesterone) for the treatment of threatened and habitual abortion and menstrual disturbances. Gestovis is efficacious orally at the same dose as parenterally administered progesterone. Dosage. 10 - 20 mg. daily or as necessary. Presentation. Available in capsules of 10 and 20 mg.
- Gregory Pincus (3 September 2013). The Control of Fertility. Elsevier. pp. 221–. ISBN 978-1-4832-7088-3.
- Current Medicine and Drugs. 1962. p. 32.
Gestovis (3-cyclo-pentyl-enol ether of 17a acetoxyprogesterone) is a potent non-oestrogenic preparation but does not give very good cycle control. In doses of 20 mg daily from the fifth to twenty-fifth day of the cycle it will inhibit ovulation.
- Edgren RA, Sturtevant FM (August 1976). "Potencies of oral contraceptives". Am. J. Obstet. Gynecol. 125 (8): 1029–38. doi:10.1016/0002-9378(76)90804-8. PMID 952300.
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|
|This article about a steroid is a stub. You can help Wikipedia by expanding it.|